| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10037679 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10031602 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10025527 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10024806 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10049406 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10049407 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30000179 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30077807 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30020975 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS20031120 | HPV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | C5 |
|---|---|
| DrugBank ID | DB01257 |
| Drug Name | Eculizumab |
| Target ID | BE0000855 |
| UniProt ID | P01031 |
| Regulation Type | antibody |
| PubMed IDs | 17139284; 17016423; 19399743; 20011245; 18784156; 17989688; 20378572; 16990386; 17702897; 11752352 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, Anders RA, Rother RP, Brodsky RA, Cameron AM: Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl. 2009 May;15(5):540-3. doi: 10.1002/lt.21714.@@Kelly R, Richards S, Hillmen P, Hill A: The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911-21. Epub .@@Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R: FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008 Sep;13(9):993-1000. doi: 10.1634/theoncologist.2008-0086. Epub 2008 Sep 10.@@Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-64.@@Luzzatto L, Risitano AM, Notaro R: Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica. 2010 Apr;95(4):523-6. doi: 10.3324/haematol.2009.017848.@@Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43.@@Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1;110(12):4123-8. Epub 2007 Aug 16.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA164776637 |
| ChEMBL | CHEMBL1201828 |
